MGMT and central nervous system cancer: A significant asymmetric distribution was observed in the malignant progression of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, 1p/19q co-deletion status, IDH mutation status, glioma grading, and histological types of samples with elevated expression levels of GJC1 in both the CGGA and TCGA datasets (Figures 1A,B).